PROCEPT BioRobotics Corp. Hits New 52-Week Low at $35.53

PROCEPT BioRobotics Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 35.53 as of September 25, 2025. This marks a significant decline, with the stock's performance over the past year showing a decrease of 46.11%, contrasting sharply with the S&P 500's gain of 15.79% during the same period.
Despite the recent downturn, PROCEPT BioRobotics has reported positive results for the last seven consecutive quarters. However, the company remains in a loss-making position, reflected in its negative price-to-earnings ratio and a return on equity of -21.80%. The stock's price-to-book ratio stands at 5.61, indicating a premium valuation relative to its book value.

The company has a market capitalization of USD 2,165 million and carries a debt-to-equity ratio of -0.65, suggesting a strong reliance on equity financing. With institutional holdings at 100%, PROCEPT BioRobotics is closely monitored by investors who typically have the resources to analyze the company's fundamentals more effectively than retail investors. Overall, the stock's performance indicates a challenging environment, with both short-term and long-term results falling below expectations.